EUVIMEDEUVIMED entdecken
Crossref

Teprotumumab improves light sensitivity in patients with thyroid eye disease

Emanuil Parunakian, Shoaib Ugradar, Joseph Tolentino, Emil Malkhasyan, Pershanjit Raika, Joseph Ghaly, Chirag Bisht, Raymond S Douglas

Graefe's Archive for Clinical and Experimental Ophthalmology · 2024

DOI: 10.1007/s00417-024-06491-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Emanuil Parunakian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice, Beverly Hills, CA, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Teprotumumab, a novel IGF-1R antibody, has been shown to significantly reduce the signs of acute and chronic Thyroid Eye Disease (TED). Light sensitivity is a reported symptom in patients with TED. There is a lack of a prospective study that has explored the effects on light sensitivity in a large cohort of patients with acute and chronic TED following treatment with teprotumumab. METHODS: Consecutive patients who were diagnosed with TED and reported light sensitivity at baseline were considered for study eligibility. All patients had measurements of Visual Light Sensitivity Questionnaire-8 (VLSQ-8), proptosis, clinical activity score (CAS), and MRD1 (distance between the upper eyelid margin and corneal reflex, mm) and MRD2 (distance between the lower eyelid margin and corneal reflex, mm) before and after treatment. RESULTS: Ninety patients (41 acute, 49 chronic) met the inclusion criteria. The mean (SD) age was 47.3 (14.3). Eighty-six (95.6%) patients completed all 8 infusions. There was a significant reduction in the total score and across all categories of the VLSQ-8 (p < 0.01 for all). Seventy-two (80%) patients had a clinically significant improvement (≥2 reduction) in at least one category. There was no significant difference in the total VLSQ-8 score between the acute and chronic group (p = 0.8). CONCLUSION: Teprotumumab improves light sensitivity in patients with acute and chronic TED. The results of this study highlight that the improvements in light sensitivity following treatment are not directly related to the mechanical changes in TED, suggesting another underlying mechanism is potentially involved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedProspective StudiesTreatment OutcomeSurveys and QuestionnairesAdultFollow-Up StudiesAgedVisual Acuity

Stichwörter der Autor:innen

OrbitThyroidThyroid eye diseaseThyroid eye disease treatment

Substanzen

teprotumumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Private Practice, Beverly Hills, CA, USA.
  • Private Practice, Beverly Hills, CA, USA. raymonddouglasmd@gmail.com.

Zitieren

APA

Parunakian, E., Ugradar, S., Tolentino, J., Malkhasyan, E., Raika, P., Ghaly, J., Bisht, C., & Douglas, R. S. (2024). Teprotumumab improves light sensitivity in patients with thyroid eye disease. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06491-0

Vancouver

Parunakian E, Ugradar S, Tolentino J, Malkhasyan E, Raika P, Ghaly J, et al. Teprotumumab improves light sensitivity in patients with thyroid eye disease. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06491-0

BibTeX
@article{Parunakian2024,
  author = {Parunakian, Emanuil and Ugradar, Shoaib and Tolentino, Joseph and Malkhasyan, Emil and Raika, Pershanjit and Ghaly, Joseph and Bisht, Chirag and Douglas, Raymond S},
  title = {Teprotumumab improves light sensitivity in patients with thyroid eye disease},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2024},
  doi = {10.1007/s00417-024-06491-0}
}
Kostenlos starten →